Navigation Links
Potential concern about drugs in clinical trial
Date:12/19/2011

Drugs that enhance levels of small molecules derived naturally in the body from a major component of animal fats (small molecules known as epoxyeicosatrienoic acids [EETs]) are currently in clinical trials for the treatment of high blood pressure and diabetes. A team of researchers led by Dipak Panigrahy and Mark Kieran, at the Dana-Farber Cancer Institute, Boston; Sui Huang, at the Institute for Systems Biology, Seattle; and Darryl Zeldin, at the National Institute of Environmental Health Science, Research Triangle Park has now generated data in mice that raise concern about the use of these drugs in humans.

The key observation of the team was that EETs promote primary tumor growth and spread to distant sites (metastasis) in a variety of mouse models of cancer. As noted by the authors and, in an accompanying commentary, Raymond DuBois and Dingzhi Wang, at The University of Texas MD Anderson Cancer Center, Houston, the data generated suggest not only that raising levels of EETs in humans could have severe adverse effects but also that EET antagonists could provide a new approach to preventing and treating metastasis.


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
2. Study participants at risk for Alzheimers want to know their potential fate
3. Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
4. NTU-led research probes potential link between cancer and a common chemical in consumer products
5. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
6. NIH-funded scientists identify potential malaria drug candidates
7. New smart material could help tap medical potential of tissue-penetrating light
8. Canadian researchers find potential new leukemia treatment with old antibiotic drug
9. Researchers reveal potential treatment for sickle cell disease
10. Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease
11. Fighting fire with fire: Vampire bacteria has potential as living antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Knowledge is God’s ... guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene ... novels, and poetry collections. , “I have been writing since high school and ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All ... is the creation of published author, Keith C. A. Tucker, son of Minister Delores ... World Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, I ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, ... Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The Aerolib ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... ... 2016-2026: Opportunities for Leading Companies – our new study ... report discusses issues and events affecting the Alzheimer,s disease ... analyses to answer these key questions: - How is ...
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
Breaking Medicine Technology: